Should I buy or sell Biodesix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BDSX shares. View BDSX analyst ratings or view top-rated stocks .

What is Biodesix's stock price target for 2024?

3 brokers have issued 1 year price targets for Biodesix's shares. Their BDSX share price targets range from $3.50 to $3.50. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 180.0% from the stock's current price. View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts .

How have BDSX shares performed in 2024?

Biodesix's stock was trading at $1.84 at the beginning of 2024. Since then, BDSX shares have decreased by 32.1% and is now trading at $1.25. View the best growth stocks for 2024 here .

Are investors shorting Biodesix?

Biodesix saw a increase in short interest in March. As of March 31st, there was short interest totaling 277,400 shares, an increase of 53.2% from the March 15th total of 181,100 shares. Based on an average daily trading volume, of 163,400 shares, the short-interest ratio is currently 1.7 days. Approximately 1.1% of the company's shares are sold short. View Biodesix's Short Interest .

When is Biodesix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BDSX earnings forecast .

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) issued its earnings results on Friday, March, 1st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business earned $14.67 million during the quarter, compared to analysts' expectations of $15.76 million. Biodesix had a negative net margin of 106.23% and a negative trailing twelve-month return on equity of 29,379.44%.

What guidance has Biodesix issued on next quarter's earnings?

Biodesix issued an update on its FY 2024 earnings guidance on Friday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.0 million-$68.0 million, compared to the consensus revenue estimate of $64.5 million.

When did Biodesix IPO?

Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free BDSX Stock Alerts

$1.25

+0.04 (+3.31%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.20
▼
$1.26
50-Day Range: $1.21
▼
$1.85
52-Week Range: $1.03
▼
$2.21

Volume: 45,431 shs
Average Volume: 153,387 shs
Market Capitalization: $121.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Get Biodesix alerts:

Biodesix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 180.0% Upside
$3.50 Price Target
Short Interest: Healthy
1.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 3 Articles This Week
Insider Trading: Selling Shares
$173,034 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.44) to ($0.38) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

501st out of 918 stocks

Diagnostics & Research Industry

1st out of 4 stocks

3.5

Analyst's Opinion

Consensus Rating
Biodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biodesix has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.12% of the float of Biodesix has been sold short.
Short Interest Ratio / Days to Cover
Biodesix has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biodesix has recently increased by 53.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biodesix does not currently pay a dividend.
Dividend Growth
Biodesix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BDSX.

2.6

News and Social Media Coverage

News Sentiment
Biodesix has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Biodesix this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,034.00 in company stock.
Percentage Held by Insiders
63.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.96% of the stock of Biodesix is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biodesix are expected to grow in the coming year, from ($0.44) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biodesix is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biodesix is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biodesix has a P/B Ratio of 25.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Biodesix Stock (NASDAQ:BDSX)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

BDSX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BDSX Stock News Headlines

April 17, 2024 | americanbankingnews.com

Biodesix (NASDAQ:BDSX) and Personalis (NASDAQ:PSNL) Critical Analysis

April 13, 2024 | finance.yahoo.com

The recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 9, 2024 | businesswire.com

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

April 5, 2024 | markets.businessinsider.com

S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher

April 5, 2024 | markets.businessinsider.com

Gold Surges Over 1%; Biodesix Shares Plummet

April 5, 2024 | businesswire.com

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

March 25, 2024 | businesswire.com

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 4, 2024 | finance.yahoo.com

Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript

March 3, 2024 | finance.yahoo.com

Biodesix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 1, 2024 | finance.yahoo.com

Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin

March 1, 2024 | businesswire.com

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

February 26, 2024 | businesswire.com

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

February 16, 2024 | finance.yahoo.com

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

February 16, 2024 | businesswire.com

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

February 13, 2024 | finance.yahoo.com

Biodesix Inc CEO Scott Hutton Sells 64,390 Shares

February 2, 2024 | finance.yahoo.com

One Biodesix Insider Raised Their Stake In The Previous Year

November 14, 2023 | finance.yahoo.com

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

November 9, 2023 | finance.yahoo.com

Biodesix to Participate in Two Upcoming Investor Conferences in November

November 7, 2023 | finance.yahoo.com

Biodesix Announces Third Quarter 2023 Results and Highlights

November 6, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Biodesix's earnings

October 24, 2023 | finance.yahoo.com

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

October 3, 2023 | finance.yahoo.com

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

September 7, 2023 | finance.yahoo.com

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

August 26, 2023 | finance.yahoo.com

Jack Schuler Spends US$217k On Biodesix Stock

August 22, 2023 | finance.yahoo.com

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

See More Headlines

Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: NASDAQ:BDSX
CUSIP: N/A
CIK: 1439725
Web: www.biodesix.com
Phone: 303-417-0500
Fax: N/A
Employees: 217
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.50
High Stock Price Target: $3.50
Low Stock Price Target: $3.50
Potential Upside/Downside: +180.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,150,000.00
Net Margins: -106.23%
Pretax Margin: -106.23%
Return on Equity: -29,379.44%
Return on Assets: -58.96%

Debt

Debt-to-Equity Ratio: 7.69
Current Ratio: 1.19
Quick Ratio: 1.19

Sales & Book Value

Annual Sales: $49.09 million
Price / Sales: 2.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.05 per share
Price / Book: 25.00

Miscellaneous

Outstanding Shares: 96,940,000
Free Float: 35,093,000
Market Cap: $121.18 million
Optionable: Optionable
Beta: 1.13

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Scott Hutton (Age 52)
President, CEO & Director
Comp: $632k
Ms. Robin Harper Cowie (Age 44)
CFO, Secretary & Treasurer
Comp: $390.87k
Dr. Heinrich Röder
Founder & CTO
Mr. Christopher Vazquez
VP, Controller & Chief Accounting Officer
Mr. Mark DeBlock
Vice President of Sales
Mr. Robbie Lunt
Senior Director of Marketing
Ms. Jessica Olbricht
Senior Director of Human Resources
Dr. Gary Anthony Pestano Ph.D. (Age 57)
Chief Development Officer
Ms. Bobbi Coffin
Chief Growth Officer
Dr. James R. Jett M.D.
Co-Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BDSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings or view top-rated stocks.
What is Biodesix's stock price target for 2024?: 3 brokers have issued 1 year price targets for Biodesix's shares. Their BDSX share price targets range from $3.50 to $3.50. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 180.0% from the stock's current price.
View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts.
How have BDSX shares performed in 2024?: Biodesix's stock was trading at $1.84 at the beginning of 2024. Since then, BDSX shares have decreased by 32.1% and is now trading at $1.25.
View the best growth stocks for 2024 here.
Are investors shorting Biodesix?: Biodesix saw a increase in short interest in March. As of March 31st, there was short interest totaling 277,400 shares, an increase of 53.2% from the March 15th total of 181,100 shares. Based on an average daily trading volume, of 163,400 shares, the short-interest ratio is currently 1.7 days. Approximately 1.1% of the company's shares are sold short.
View Biodesix's Short Interest.
When is Biodesix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BDSX earnings forecast.

How were Biodesix's earnings last quarter?: Biodesix, Inc. (NASDAQ:BDSX) issued its earnings results on Friday, March, 1st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business earned $14.67 million during the quarter, compared to analysts' expectations of $15.76 million. Biodesix had a negative net margin of 106.23% and a negative trailing twelve-month return on equity of 29,379.44%.
What guidance has Biodesix issued on next quarter's earnings?: Biodesix issued an update on its FY 2024 earnings guidance on Friday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.0 million-$68.0 million, compared to the consensus revenue estimate of $64.5 million.
When did Biodesix IPO?: Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
How do I buy shares of Biodesix?: Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDSX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biodesix (BDSX) Stock Price, News & Analysis

Biodesix MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biodesix Stock (NASDAQ:BDSX)

BDSX Stock Price History

BDSX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BDSX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™